Physician profile
Robert W Byrd
NPI 1801964630
$2,326.55
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203 · 2020: $88.43 · 2021: $828 · 2022: $645 · 2023: $524 · 2024: $38.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $562.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $304.91 | 2021-2023 | Relistor |
| Grt US Holding, INC. | $271.73 | 2020-2022 | |
| Amgen INC. | $250.98 | 2019-2022 | |
| Abbvie INC. | $200.98 | 2022-2023 | Ubrelvy, Qulipta, Botox |
| Nevro Corp. | $193.26 | 2019-2022 | |
| Pfizer INC. | $157.53 | 2021-2023 | |
| Lilly USA, LLC | $114.63 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $95.71 | 2022 | |
| Lundbeck LLC | $89.63 | 2022-2023 | Vyepti |
| Medtronic USA, INC. | $89.39 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $61.25 | 2021 | |
| Tersera Therapeutics LLC | $49.31 | 2021-2023 | Prialt |
| Scilex Pharmaceuticals INC. | $45.56 | 2021-2022 | |
| Daiichi Sankyo INC. | $43.67 | 2019 | |
| Allergan, INC. | $43.18 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $38.34 | 2022-2023 | Ajovy |
| Saluda Medical Americas, INC. | $38.12 | 2024 | Evoke |
| Stimwave Technologies Incorporated | $34.78 | 2021 | |
| Pacira Therapeutics, INC. | $29.43 | 2021 | |
| Ibsa Pharma INC. | $26.89 | 2021 | |
| Medtronic, INC. | $21.70 | 2023 | Intellis Adaptivestim |
| Si-Bone, INC. | $18.90 | 2020 | |
| Collegium Pharmaceutical, INC. | $18.51 | 2023 | Belbuca |
| Azurity Pharmaceuticals, INC. | $17.21 | 2023 | Horizant |
| Pacira Pharmaceuticals Incorporated | $16.63 | 2022 | |
| Biodelivery Sciences International, INC. | $15.65 | 2021 | |
| Boston Scientific Corporation | $15.07 | 2022 | |
| Vertos Medical, INC. | $12.19 | 2019 | |
| Bioventus LLC | $11.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Byrd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.